九洲药业：关于2025年前三季度计提资产减值准备的公告

Core Viewpoint - Jiuzhou Pharmaceutical announced a necessary impairment test and assessment of assets to accurately reflect its financial status as of September 30, 2025, in accordance with accounting standards and company policies [1] Group 1: Impairment Testing - The company and its subsidiaries will conduct impairment tests on assets showing signs of impairment [1] - Based on the principle of prudence, the company will make provisions for potential asset impairment losses [1] Group 2: Credit Impairment Losses - According to the accounting standards, the company will recognize credit impairment losses on receivables and other receivables based on expected credit losses [1] - For the first three quarters of 2025, the company has recorded a credit impairment loss of 20.8376 million yuan [1]